Lupin does it again
Shital Jibhe / 16 Feb 2017
The Indian pharmaceutical company, Lupin has announced that the Company has received USFDA approval for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (syrup), 5 mg/1.5 mg per 5 ml, Generic of Hycodan Oral Solution and 5 mg/1.5 mg per 5 mL of Endo Pharmaceuticals.
The Indian pharmaceutical company, Lupin has announced that the Company has received USFDA approval for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (syrup), 5 mg/1.5 mg per 5 ml, Generic of Hycodan Oral Solution and 5 mg/1.5 mg per 5 mL of Endo Pharmaceuticals.
In a period of one year, the stock has delivered negative returns of 17.99 per cent and underperformed the BSE Sensex and BSE Healthcare index.
Lupin Limited is a transnational pharmaceutical company based in Mumbai. It is the seventh-largest company by market capitalisation and the tenth largest generic pharmaceutical company by revenue globally.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.